The 3 Best S&P 500 Stocks to Buy Now

The article is broadly bullish on Amazon, Visa, and Eli Lilly, citing strong operational momentum and attractive valuations. Amazon’s AWS revenue rose 28% year over year in Q1, Visa processed 66 billion transactions with revenue up 17%, and Eli Lilly’s Q1 revenue surged 56% alongside FDA approval for its Foundayo GLP-1 pill. The piece is mainly an investment thesis rather than new market-moving news, so immediate price impact should be limited.

Analysis

The market is underappreciating how these three names sit on different layers of the same digital-transaction stack. AMZN is the compute-and-fulfillment layer: if enterprise AI and consumer habit formation keep compounding, the real lever is not revenue growth but incremental margin expansion from fixed-cost absorption in cloud plus denser last-mile utilization. That makes it more resilient than a simple retail/AI proxy; downside only becomes meaningfully convex if capex rises faster than monetization for several quarters.

V is the toll-collection layer, but the second-order opportunity is not just payment volume; it is security, identity, and authorization in machine-to-machine commerce. If agentic AI produces a step-function increase in low-value, high-frequency transactions, the firms with the cleanest fraud models and the broadest acceptance rails gain share while alternative payment methods still face trust and interoperability constraints. The key risk is regulatory or platform disintermediation, but that is a multi-year threat, not a next-quarter one.

LLY remains the highest-quality duration asset here, but the market may be too focused on obesity alone and too little on the pipeline optionality from adjacent therapeutic categories. The more important second-order effect is pricing power: if supply remains tight, every incremental formulation improvement or compliance enhancement can re-rate the franchise because it expands the addressable pool without requiring a major channel change. The overhang is competitive intensity in GLP-1s; if peers close the tolerability gap faster than expected, the multiple is vulnerable even if absolute earnings keep rising.

Contrarian take: the setup is less about 'buy the winners' and more about which winner has the longest reinvestment runway. AMZN and V look less stretched than the market thinks because both can compound through infrastructure-like economics, while LLY already discounts a lot of execution and may need continued pipeline beats to sustain multiple expansion. The cleanest expression is to own the secular compounders and avoid chasing the most crowded healthcare growth narrative without a hedge.

Key Decisions for Investors

• Long AMZN into the next 3-6 months on weakness; target a 2:1 upside/downside if AWS re-accelerates and retail margin leverage persists. Use size discipline because a capex surprise could compress the multiple before earnings catch up.
• Long V vs. short a low-quality payments/fintech basket over 6-12 months; the network + fraud/data advantage should widen as AI transaction counts rise. Prefer the pair over outright long to isolate the secular payment-ramp catalyst from macro beta.
• Take a tactical long LLY call spread 3-6 months out; upside is best if pipeline news or GLP-1 formulation adoption improves, but cap the premium because the stock already prices strong earnings durability.
• Avoid chasing NVDA/INTC/UBER on this headline; their linkage is indirect and the current data shows the market is assigning them low immediate benefit. Better to express the theme through AMZN and V where the monetization path is clearer.
• If AMZN and V both gap higher on the same AI commerce narrative, consider trimming into strength and rotating a portion into cash or LLY after a pullback; the former have better multi-year optionality, but the latter may offer better entry after the crowd buys the story.